THL – TorHoerman Law

Invokana Risks Push Doctors to Switch Patients to Other Medications


The SGLT2 inhibitor Invokana has come under fire recently because of the increased risk of lower limb amputations caused by one of its key ingredients, canagliflozin. Physicians in California are hurrying to switch patients from Invokana to other dia Read More »

AstraZeneca’s Farxiga Safety Claims Contradict FDA Findings


Last month at the American Diabetes Association’s (ADA) 77th Scientific Sessions, AstraZeneca Plc. presented new data supporting the safety and effectiveness of their SLGT-2 inhibitor Farxiga. This data is in direct contention with the FDA̵ Read More »

Invokana Black Box Warning Issued by U.S. Food & Drug Administration


  Invokana Black Box Warning Pharmaceutical manufacturer Johnson & Johnson’s Invokana (“the SGLT-2 canagliflozin pharmaceutical marketed to treat type 2 diabetes and off-label for type 1 diabetes”), along with related drugs Read More »

Filter News

No-Obligation Free Consultation

Contact us by phone at 1-888-508-6752 or email us below.

Sidebar Contact